Passage BIO, Inc. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2021-12-08

Reporting Person: Quigley Jill M. (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-08	Common Stock	M	71975	$0.23	Acquired	368754	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Employee Stock Option (right to buy)	$0.23	M	11193	Disposed	2029-02-06	Common Stock (11193)	Direct
2021-12-08	Employee Stock Option (right to buy)	$0.23	M	60782	Disposed	2029-02-06	Common Stock (60782)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3608	Indirect

Footnotes

F1: Includes 367,259 of common stock, of which 88,488 shares are unvested and subject to repurchase by the Issuer if the reporting person ceases to provide services to the Issuer prior to the vesting of the shares.

F2: Includes 1,495 shares acquired under the 2020 Employee Stock Purchase Plan on May 14, 2021.

F3: The option vested as to 25% of the total shares on November 12, 2019 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on November 12, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.

F4: The option vests as to 25% of the total shares on May 8, 2020 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on May 8, 2023 subject to the reporting person's provision of service to the issuer on each vesting date.